Sarepta Therapeutics Inc. (SRPT) Earns “Outperform” Rating from Robert W. Baird
Sarepta Therapeutics Inc. (NASDAQ:SRPT)‘s stock had its “outperform” rating reiterated by analysts at Robert W. Baird in a research report issued to clients and investors on Monday. They presently have a $102.00 target price on the stock. Robert W. Baird’s target price suggests a potential upside of 95.10% from the company’s current price.
Other equities research analysts have also issued reports about the company. Leerink Swann upgraded Sarepta Therapeutics from an “underperform” rating to a “market perform” rating and set a $50.00 price objective on the stock in a research report on Monday, September 19th. Piper Jaffray Cos. upgraded Sarepta Therapeutics from a “neutral” rating to an “overweight” rating in a research report on Monday, September 19th. Janney Montgomery Scott set a $30.00 price objective on Sarepta Therapeutics and gave the stock a “hold” rating in a research report on Wednesday, August 3rd. William Blair upgraded Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and set a $88.00 price objective on the stock in a research report on Monday, September 19th. Finally, Wedbush reiterated an “outperform” rating and issued a $36.00 price objective on shares of Sarepta Therapeutics in a research report on Tuesday, July 19th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $60.91.
Sarepta Therapeutics (NASDAQ:SRPT) traded down 4.44% during midday trading on Monday, reaching $49.96. The company had a trading volume of 2,848,133 shares. Sarepta Therapeutics has a 12-month low of $8.00 and a 12-month high of $63.73. The stock’s market capitalization is $2.39 billion. The company has a 50-day moving average of $45.03 and a 200-day moving average of $26.60.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/17/sarepta-therapeutics-inc-srpt-earns-outperform-rating-from-robert-w-baird.html
Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Tuesday, July 19th. The company reported ($1.35) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.19) by $0.16. During the same period last year, the firm earned ($0.87) earnings per share. On average, analysts predict that Sarepta Therapeutics will post ($4.23) EPS for the current fiscal year.
In other Sarepta Therapeutics news, CEO Edward M. Md Kaye sold 40,179 shares of the business’s stock in a transaction dated Thursday, September 22nd. The stock was sold at an average price of $60.00, for a total transaction of $2,410,740.00. Following the completion of the sale, the chief executive officer now owns 117,162 shares of the company’s stock, valued at $7,029,720. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP David T. Howton sold 7,000 shares of the business’s stock in a transaction dated Thursday, September 22nd. The shares were sold at an average price of $60.00, for a total value of $420,000.00. Following the sale, the senior vice president now directly owns 28,453 shares of the company’s stock, valued at approximately $1,707,180. The disclosure for this sale can be found here. Corporate insiders own 10.90% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the stock. TIAA CREF Investment Management LLC raised its stake in Sarepta Therapeutics by 5.5% in the first quarter. TIAA CREF Investment Management LLC now owns 216,707 shares of the company’s stock valued at $4,230,000 after buying an additional 11,334 shares in the last quarter. Franklin Resources Inc. bought a new stake in Sarepta Therapeutics during the first quarter valued at about $13,506,000. BlackRock Fund Advisors raised its stake in Sarepta Therapeutics by 2.2% in the first quarter. BlackRock Fund Advisors now owns 1,661,818 shares of the company’s stock valued at $32,439,000 after buying an additional 36,371 shares in the last quarter. BlackRock Institutional Trust Company N.A. raised its stake in Sarepta Therapeutics by 2.5% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 1,068,913 shares of the company’s stock valued at $20,865,000 after buying an additional 25,799 shares in the last quarter. Finally, State Street Corp raised its stake in Sarepta Therapeutics by 54.0% in the first quarter. State Street Corp now owns 2,467,376 shares of the company’s stock valued at $48,168,000 after buying an additional 865,658 shares in the last quarter. 65.06% of the stock is owned by institutional investors and hedge funds.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.